证券代码：000912 证券简称：泸天化 公告编号：2025-027 四川泸天化股份有限公司 关于持股 5%以上股东增持股份触及 1%整数倍的 公 告 公司股东泸州产业发展投资集团有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 2025 年 5 月 26 日，公司收到泸州发展集团出具的《关于增持股份触及 1% 整数倍的告知函》，泸州发展集团于 2025 年 5 月 15 日至 2025 年 5 月 23 日期间 通过深圳证券交易所系统以集中竞价交易方式增持公司股票 1,209.8 万股，占总 股本的 0.77%，触及 1%的整数倍。本次增持计划尚未实施完毕，泸州发展集团将 继续实施增持计划。现将有关情况公告如下： | 1．基本情况 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 信息披露义务人 | 泸州产业发展投资集团有限公司 | | | | | | | | | | 住所 | 四川 ...

Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]

四川泸天化股份有限公司 关于持股 5%以上股东增持股份触及 1%整数倍的 公告 公司股东泸州产业发展投资集团有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 | 1．基本情况 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 信息披露义务人 | | | 泸州产业发展投资集团有限公司 | | | | | | | | 住所 | 四川省泸州市江阳区龙腾路 | | | | | | 10 | 号 | | | 权益变动时间 | 26 | 2024 年 12 月 | 日至 | 2025 | 年 | 5 | 月 | 14 | 日 | | 价值的认可，泸州发展集团自 | 2024 年 12 月 月内以自有资金和自筹资金通过深圳证券交易所允许的 | | 26 | | 日起六个 | | --- | --- | --- | --- | --- | --- | | | 方式增持公司股份（拟增持价格不超过 6.8 | | | | 元/股，计划 | | 权益变动过程 | 增持金额不 ...

泸天化（000912）公告，公司持股5%以上股东泸州产业发展投资集团有限公司于2024年12月26日至 2025年5月14日期间通过深圳证券交易所系统以集中竞价交易方式累计增持公司股票1595.57万股，占总 股本的1.02%，触及1%的整数倍。本次增持计划尚未实施完毕，泸州发展集团将继续实施增持计划。 ...

Core Viewpoint - The collaboration between Shanxi Coal Chemical Institute and Sichuan Lutianhua Co., Ltd. aims to develop biomass-based long-chain alpha-olefins, addressing the high dependency on imported raw materials and high production costs associated with traditional petroleum routes [1][2]. Group 1: Project Overview - The project focuses on synthesizing long-chain alpha-olefins (C₆ and above) using biomass feedstocks, which can significantly reduce carbon emissions by over 60% compared to petroleum-based methods [2]. - The project will utilize a three-stage catalytic system involving hydrogenation, deoxygenation, and selective cracking of biomass oils, such as palm oil and waste oils [2]. Group 2: Technical Approach - The project employs a collaborative model involving research, engineering, and industrial application, with Shanxi Coal Chemical Institute leading the molecular sieve catalysis and catalyst design [3]. - The engineering phase will be supported by China Chemical SEDIN Engineering, ensuring continuous operation of the pilot plant for over 1,000 hours [3]. Group 3: Market and Product Focus - The products from this project will target high-value chemical markets, including high-end lubricants, oilfield additives, and environmentally friendly plasticizers, directly competing with major international players like ExxonMobil and Shell [1][2]. - Sichuan Lutianhua has a comprehensive production capacity across various chemical products, positioning it well to integrate biomass-based chemical production into its existing operations [4]. Group 4: Strategic Importance - The initiative aligns with China's "dual carbon" strategy, emphasizing the importance of biomass-based chemicals in global technological competition and industrial upgrading [1][2]. - The project aims to create a biomass-based fine chemical industry cluster, enhancing the overall value chain in the chemical sector [5].

证券代码：000912 证券简称：泸天化 公告编号：2025-025 四川泸天化股份有限公司 关于回购公司股份进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 四川泸天化股份有限公司（以下简称"公司"）于2024年6月20日召开2023 年度股东大会，审议通过了《四川泸天化股份有限公司回购股份方案》，同意公 司使用自有资金以集中竞价交易方式回购公司部分股份，回购资金总额不低于人 民币8,000万元（含），不超过人民币15,000万元（含），回购价格不超过人民 币6.09元/股（含本数），本次回购股份将用于股权激励。本次回购股份的实施 期限自2023年度股东大会审议通过回购股份方案之日起12个月内（2025年6月19 日止）。具体回购股份的金额和数量以回购结束时实际回购的金额和股份数量为 准。公司已在中国证券登记结算有限责任公司深圳分公司开立股份回购专用证券 账户并披露了《回购报告书》。2024年7月15日，公司实施了首次回购，具体内 容详见公司于2024年7月16日在巨潮资讯网（www.cninfo.com.cn）上披露的《四 川泸天化股份有限公司关于首次 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 1,502,233,683.30, representing a 16.64% increase compared to CNY 1,287,943,525.81 in the same period last year[4]. - Net profit attributable to shareholders was CNY 36,829,205.80, up 10.26% from CNY 33,401,138.82 year-on-year[4]. - The basic earnings per share remained stable at CNY 0.02, unchanged from the previous year[4]. - Total operating revenue for the current period reached ¥1,502,233,683.30, an increase of approximately 16.6% from ¥1,287,943,525.81 in the previous period[18]. - Net profit for the current period was ¥36,733,966.00, up from ¥33,414,496.21, reflecting a growth of about 9.0%[19]. Cash Flow - The net cash flow from operating activities surged by 486.52% to CNY 71,031,055.55, compared to CNY 12,110,612.17 in the previous year[4]. - Cash flow from operating activities was ¥1,725,810,429.87, compared to ¥1,314,214,134.13 in the previous period, indicating a significant increase of approximately 31.3%[20]. - Net cash flow from operating activities increased to ¥71,031,055.55 from ¥12,110,612.17 year-over-year, representing a significant improvement[21]. - Total cash inflow from investment activities was ¥786,240,439.03, up from ¥559,052,104.52, indicating a positive trend in investment recovery[21]. - Cash outflow for investment activities decreased to ¥347,044,025.71 from ¥635,765,980.90, resulting in a net cash flow from investment activities of ¥439,196,413.32 compared to a negative cash flow last year[21]. - Cash inflow from financing activities was ¥260,000,000.00, a substantial increase from ¥15,100,000.00, reflecting enhanced financing efforts[22]. - Net cash flow from financing activities was -¥203,626,074.80, an improvement from -¥498,929,461.34, indicating better management of financing costs[22]. Assets and Liabilities - The total assets decreased by 6.19% to CNY 9,586,777,820.59 from CNY 10,219,298,716.97 at the end of the previous year[4]. - Total liabilities decreased to ¥3,166,643,694.88 from ¥3,839,987,631.29, a reduction of approximately 17.5%[17]. - The company's total equity increased to ¥6,420,134,125.71 from ¥6,379,311,085.68, showing a growth of about 0.6%[17]. - Total current assets decreased from CNY 5,300,497,742.79 to CNY 4,710,827,516.60, a reduction of approximately 11.09%[14][15]. - Cash and cash equivalents decreased from CNY 2,191,758,926.98 to CNY 1,999,717,610.68, a decline of about 8.77%[14]. - Total current liabilities amounted to ¥2,750,656,316.06, down from ¥3,310,140,063.68, a decrease of about 17.0%[17]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 42,072[11]. - The largest shareholder, Luzhou Tianhua (Group) Co., Ltd., holds 15.09% of shares, totaling 236,550,393 shares[11]. Operational Efficiency - Management expenses decreased by 52.00% to CNY 48,191,176.34, reflecting improved internal controls[9]. - Research and development expenses decreased to ¥4,771,975.09 from ¥9,961,370.81, a reduction of about 52.1%[18]. - The company reported a significant increase in accounts receivable financing, which rose by 777.10% to CNY 43,547,689.23[8]. Market and Product Development - The company has not reported any new product developments or market expansion strategies in the current period[13].

四川泸天化股份有限公司独立董事向朝阳 2024 年度独立性自查报告 本人向朝阳，于 2024 年 2 月 27 日起任职四川泸天化股 份有限公司（以下简称"公司"）独立董事，在 2024 年度任职 时间为 2024 年 2 月 27 日至 2024 年 12 月 31 日。本人严格 遵守《公司法》《上市公司治理准则》和《上市公司独立董 事管理办法》等法律规定以及《公司章程》对独立董事的任 职要求，持续保持独立性。2024 年度独立性自查情况如下： | 序号 | 事项 | | 自查结果 | | | --- | --- | --- | --- | --- | | 1 | 在上市公司或者其附属企业任职的人员及其 | 是 | 否 |  | | | 配偶、父母、子女、主要社会关系； | | | | | 2 | 直接或者间接持有上市公司已发行股份百分 | 是 | 否 |  | | | 之一以上或者是上市公司前十名股东中的自 | | | | | | 然人股东及其配偶、父母、子女； | | | | | 3 | 在直接或者间接持有上市公司已发行股份百 分之五以上的股东或者在上市公司前五名股 | 是 | 否 |  | ...

2024 年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引的规定和要求，结 合四川泸天化股份有限公司（以下简称"公司"）《内部控制手册》 和《内控自我评价手册》，以及内控体系涉及的相关制度和评价办法， 在内部控制日常监督和专项监督的基础上，我们对公司截至 2024 年 12 月 31 日（内部控制评价报告基准日）内部控制的有效性进行了自 我评价，现将有关评价结果报告如下。 一、董事会声明 公司董事会及全体董事保证本报告内容不存在任何虚假记载、误 导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担 个别及连带法律责任。 建立健全并有效实施内部控制，评价其有效性，并如实披露内部 控制自我评价报告是公司董事会的责任；监事会对董事会建立和实施 内部控制进行监督；经理层负责组织领导企业内部控制的日常运行。 公司内部控制的目标是：合理保证经营管理合法合规、资产安全、 财务报告及相关信息真实完整，提高经营效率和效果，促进实现发展 战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或 对控制政策和程序遵循的程度降低，根据内部控制 ...

四川泸天化股份有限公司独立董事王积慧 如上述任何一项填写为"是"，请在以下就具 体事宜进行详细解释： 2024 年度独立性自查报告 本人王积慧，于 2024 年 2 月 27 日起任职四川泸天化股 份有限公司（以下简称"公司"）独立董事，在 2024 年度任职 时间为 2024 年 2 月 27 日至 2024 年 12 月 31 日。本人严格 遵守《公司法》《上市公司治理准则》和《上市公司独立董 事管理办法》等法律规定以及《公司章程》对独立董事的任 职要求，持续保持独立性。2024 年度独立性自查情况如下： | 序号 | 事项 | | 自查结果 | | | --- | --- | --- | --- | --- | | 1 | 在上市公司或者其附属企业任职的人员及其 | 是 | 否 |  | | | 配偶、父母、子女、主要社会关系； | | | | | 2 | 直接或者间接持有上市公司已发行股份百分 之一以上或者是上市公司前十名股东中的自 | 是 | 否 |  | | | 然人股东及其配偶、父母、子女； | | | | | 3 | 在直接或者间接持有上市公司已发行股份百 分之五以上的股东或者在上市公 ...